ES2575549T3 - Comprimido de melatonina y métodos de preparación y uso - Google Patents

Comprimido de melatonina y métodos de preparación y uso Download PDF

Info

Publication number
ES2575549T3
ES2575549T3 ES08742710.0T ES08742710T ES2575549T3 ES 2575549 T3 ES2575549 T3 ES 2575549T3 ES 08742710 T ES08742710 T ES 08742710T ES 2575549 T3 ES2575549 T3 ES 2575549T3
Authority
ES
Spain
Prior art keywords
melatonin
dissolved
dosage form
pharmaceutically acceptable
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08742710.0T
Other languages
English (en)
Spanish (es)
Inventor
John A. Mccarty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2575549T3 publication Critical patent/ES2575549T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES08742710.0T 2007-04-11 2008-04-10 Comprimido de melatonina y métodos de preparación y uso Active ES2575549T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92292107P 2007-04-11 2007-04-11
US922921P 2007-04-11
PCT/US2008/004615 WO2008127609A1 (en) 2007-04-11 2008-04-10 Melatonin tablet and methods of preparation and use

Publications (1)

Publication Number Publication Date
ES2575549T3 true ES2575549T3 (es) 2016-06-29

Family

ID=39864239

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08742710.0T Active ES2575549T3 (es) 2007-04-11 2008-04-10 Comprimido de melatonina y métodos de preparación y uso

Country Status (11)

Country Link
US (3) US20100119601A1 (https=)
EP (2) EP2144610B1 (https=)
JP (2) JP5600058B2 (https=)
CN (1) CN101677994B (https=)
AU (1) AU2008239683B2 (https=)
CA (1) CA2683436C (https=)
ES (1) ES2575549T3 (https=)
IL (2) IL201383A (https=)
MX (1) MX2009010878A (https=)
RU (1) RU2485949C2 (https=)
WO (1) WO2008127609A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9254294B2 (en) 2003-02-24 2016-02-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
US9358296B2 (en) 2003-02-24 2016-06-07 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US10172810B2 (en) * 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
ES2575549T3 (es) * 2007-04-11 2016-06-29 John A. Mccarty Comprimido de melatonina y métodos de preparación y uso
TR200907338A1 (tr) * 2009-09-28 2011-04-21 Yed�Tepe �N�Vers�Tes� Doğal bileşenler içeren bir film şeridi.
CN103429223A (zh) 2011-01-17 2013-12-04 武田药品工业株式会社 口腔分散片
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012109216A1 (en) 2011-02-11 2012-08-16 Zx Pharma, Llc Multiparticulate l-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
EP2570126B1 (en) * 2011-09-16 2014-03-26 Darius Rassoulian Use of melatonin for treating acute alcohol intoxication
ITMI20112042A1 (it) * 2011-11-10 2013-05-11 Eratech S R L Polvere da ricostituire prima dell'uso comprendente melatonina e preparazione iniettabile ottenibile da tale polvere.
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
CN113842362A (zh) 2012-11-14 2021-12-28 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
US20140303128A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
CA2909591C (en) 2013-04-23 2017-03-28 Zx Pharma, Llc Enteric coated multiparticulate composition with proteinaceous subcoat
ES2995732T3 (en) 2014-07-21 2025-02-11 Pharmaceutical Productions Inc Solid dosage form composition for buccal or sublingual administration of cannabinoids
CN105663061A (zh) * 2014-11-16 2016-06-15 刘佳迪 褪黑素滴丸的制法和用法
NL2015272B1 (en) * 2015-08-05 2017-05-02 Versailles B V Melatonin formulations and methods for preparation and use.
WO2018167273A1 (en) * 2017-03-16 2018-09-20 Repoceuticals Aps Compositions for retarding the decomposition of melatonin in solution
US10806789B2 (en) 2017-05-12 2020-10-20 The LIV Group Inc. Composition for enhanced absorption of supplements
BR112019027286B1 (pt) 2017-06-20 2022-02-22 Société Des Produits Nestlé S.A Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva
WO2019038586A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited PHARMACEUTICAL COMPOSITION OF MELATONIN
CN109953953B (zh) * 2017-12-22 2021-09-21 深圳大学 一种褪黑素纳米缓释给药系统的制备方法
CN111757728A (zh) * 2018-03-11 2020-10-09 纳诺洛吉卡股份公司 用于压缩的药物剂型的多孔二氧化硅颗粒
WO2021205053A1 (es) * 2020-04-09 2021-10-14 Universidad De Granada Composición inyectable de melatonina para el tratamiento de enfermedades virales
KR102506059B1 (ko) * 2020-10-20 2023-03-07 코스맥스 주식회사 멜라토닌을 포함하는 항산화용 화장료 조성물
CN112426408B (zh) * 2020-12-08 2023-12-19 广州帝奇医药技术有限公司 一种褪黑素组合物及其制备工艺
CN112870193B (zh) * 2021-03-11 2022-07-08 大连医科大学附属第二医院 褪黑素在制备治疗对靶向药物耐药的her2阳性乳腺癌的药物中的应用
JP2025119064A (ja) * 2022-04-28 2025-08-14 日本たばこ産業株式会社 無機多孔質材料を含む口腔用組成物
JP2025119063A (ja) * 2022-04-28 2025-08-14 日本たばこ産業株式会社 無機多孔質材料を含む口腔用組成物
JP2025119061A (ja) * 2022-04-28 2025-08-14 日本たばこ産業株式会社 無機多孔質材料を含む口腔用組成物
JP2025119062A (ja) * 2022-04-28 2025-08-14 日本たばこ産業株式会社 無機多孔質材料を含む口腔用組成物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
IT1243193B (it) 1990-08-10 1994-05-24 Medea Res Srl Composizioni farmaceutiche orali a base di melatonina
WO1995003043A1 (en) 1993-07-26 1995-02-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Sustained release oral compositions containing melatonin
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US5688520A (en) * 1995-03-29 1997-11-18 Minnesota Mining And Manufacturing Company Transmucosal delivery of melatonin for prevention of migraine
FR2742989B1 (fr) * 1995-12-29 1998-01-23 Adir Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs
WO1998002186A1 (en) * 1996-07-11 1998-01-22 Farmarc Nederland B.V. Inclusion complex containing indole selective serotonin agonist
US6620836B1 (en) * 1997-01-22 2003-09-16 Jay Patrick Antiarrhythmic and tranquilizer composition and treatment
JP2001518923A (ja) 1997-03-26 2001-10-16 ダブリュ エイチ エム マーカス，フランシスカス 鼻腔用メラトニン組成物
FR2762513B1 (fr) * 1997-04-23 2003-08-22 Permatec Pharma Ag Comprimes bioadhesifs
IT1298731B1 (it) 1998-03-13 2000-02-02 Recordati Chem Pharm Composizioni farmaceutiche contenenti complessi di inclusione con melatonina
JP4080686B2 (ja) * 2000-11-06 2008-04-23 株式会社リコー 画像形成装置
KR20010088917A (ko) * 2001-07-30 2001-09-29 최종욱 디지털 정보 보안 방법 및 그 시스템
IL164163A0 (en) * 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
CN1210026C (zh) * 2002-10-09 2005-07-13 重庆太极医药研究院 褪黑素双层控释片及制备工艺
EP2343045A3 (en) * 2003-02-24 2011-09-21 Pharmaceutical Productions Inc. Transmucosal drug delivery system
WO2004096177A1 (de) * 2003-05-02 2004-11-11 Globopharm Pharmazeutische Produktions- Und Handelsgesellschaft M.B.H. Feste pharmazeutische zubereitung enthaltend levothyroxin- und/oder liothyroninsalze
MXPA06003813A (es) * 2003-10-10 2006-06-14 Lifecycle Pharma As Forma solida de dosificacion que comprende un fibrato y una estatina.
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
ES2575549T3 (es) * 2007-04-11 2016-06-29 John A. Mccarty Comprimido de melatonina y métodos de preparación y uso
US20140303227A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system

Also Published As

Publication number Publication date
IL201383A (en) 2017-01-31
EP2144610B1 (en) 2016-04-06
RU2485949C2 (ru) 2013-06-27
RU2009137472A (ru) 2011-05-20
JP2010523673A (ja) 2010-07-15
JP5600058B2 (ja) 2014-10-01
IL201383A0 (en) 2010-05-31
US9381190B2 (en) 2016-07-05
EP2144610A4 (en) 2013-08-07
US20130028943A1 (en) 2013-01-31
CA2683436C (en) 2016-07-26
EP3056220A1 (en) 2016-08-17
AU2008239683A1 (en) 2008-10-23
EP2144610A1 (en) 2010-01-20
CA2683436A1 (en) 2008-10-23
US8992948B2 (en) 2015-03-31
AU2008239683B2 (en) 2014-03-27
JP2014237700A (ja) 2014-12-18
CN101677994A (zh) 2010-03-24
US20150174101A1 (en) 2015-06-25
CN101677994B (zh) 2015-07-22
IL249102A0 (en) 2017-01-31
US20100119601A1 (en) 2010-05-13
MX2009010878A (es) 2010-03-26
WO2008127609A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
ES2575549T3 (es) Comprimido de melatonina y métodos de preparación y uso
ES2500068T3 (es) Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2629306T3 (es) Tratamiento y prevención de la mucositis mediante derivados de antocianidina
ES2551307T3 (es) Composición de inhalación que contiene aclidinio para tratamiento de enfermedad pulmonar obstructiva crónica
ES2532948T3 (es) Composición tópica para el tratamiento de queratosis actínica
DOP2010000323A (es) Pirimidin-5-carboxamidas sustituidas 281
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
CO6351785A2 (es) Inhibidores de cinasa map p39
PA8842201A1 (es) Inhibidores macrocíclicos de serina proteasas de hepatitis c
CL2007001870A1 (es) Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d
BRPI0515372B8 (pt) composição líquida para fornecer anestesia local prolongada após administração a um indivíduo, e, uso de bupivacaína, acetato isobutirato de sacarose e álcool benzílico
CL2009000882A1 (es) Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer.
ES2620754T3 (es) Uso de 5-androstano (alquil)-3,5,6-triol en la preparación de fármacos neuroprotectores
CR7768A (es) Una composicion farmaceutica
AR077629A1 (es) Mimetico de smac
AR033808A1 (es) Una composicion topica de anestesia local y los parches y los envases que la contienen
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
AR056556A1 (es) Imidazo(1,2-a)piridina con actividad antiproliferacion celular
AR068044A1 (es) Derivados de catecolamina y prodrogas de los mismos
CL2008003576A1 (es) Compuestos derivados de amida del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico; composicion farmaceutica que los comprende; y usos en el tratamiento de una afeccion inflamatoria.
CO2019002555A2 (es) Composición farmacéutica
AR032586A1 (es) Composicion farmaceutica
AR111760A1 (es) Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
UY27727A1 (es) Nueva composicion farmacéutica-